Interview with Sven Dethlefs, CEO, TEVA Germany
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Address: Scheurlstraße 21 ,D-90478 Nürnberg Postbox 440138
Tel: +49 (0) 911 946469-0
Founded in 1998 by Daniel M. Perlman, RPS implemented its business plan to build the industry’s first Pharmaceutical Resource Organization model. The RPS plan was dedicated to achieving the goal of providing the biopharmaceutical industry with an alternative to traditional outsourcing models by offering customized, integrated solutions that addressed these fundamental industry challenges.The European growth of RPS allows clients to utilize the market leading integrated clinical solutions and enhanced full-service capabilities of RPS to develop clinical products beyond the Americas and into Europe for greater value generation across a global R&D pipeline. RPS recently acquired three CROs in Europe: in Germany, France and Spain. RPS entered the German market in December 2008, when they acquired Imerem GmbH. RPS has acquired Imerem’s specialist knowledge in major indications of clinical indications: CNS (neurology and psychiatry), oncology (solid, hematological tumors), transplantation, pain, dermatology. We are highly experienced in studies with phytomedicines and complementary medicinal treatments, medicinal products, and large-scale post-marketing surveillance studies. Imerem was in particular the world-wide leading CRO in research in the “Restless Legs Syndrome.”Executive Vice President of Clinical Operations in Europe and CEO of RPS Germany is Dr. Ralf Kohnen, former founder of Imerem GmbH.
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
See our Cookie Privacy Policy Here
